Experts caution against widespread use of weight loss drug due to potential euphoria side effects.

Two experts see major challenges facing the adoption of new obesity drugs.

According to Dr. Kavita Patel, a physician and NBC News medical contributor, the latest data on Ozempic's ability to delay the progression of chronic kidney disease provides the strongest evidence for using the drug for secondary purposes.

She believes that data backing the use of obesity drugs for other conditions such as Alzheimer's and alcohol addiction is insufficient.

"The trials we have on [Novo Nordisk trial] FLOW, on sleep apnea, cardiovascular risks, and diabetes control are not as robust as the data we have on these topics. These double-blind placebo, randomized controlled trials are impressive, but we still have a long way to go before we can consider them miraculous."

On Tuesday, the company announced that Ozempic had been approved by the FDA to treat chronic kidney disease in Type 2 diabetic patients, more than a year after an interim analysis showed its effectiveness.

Since its announcement, Novo Nordisk has gained 9.82% while its obesity drug competitor has increased by 5.16% as of Friday's close.

The medication's approval for uses beyond diabetes management is hindered by the belief that efficacy is a significant obstacle.

According to Patel, who was previously the White House Health Policy Director under President Obama, while we know this drug is effective in treating diabetics, there are numerous obstacles to its use, such as cost, adherence, and prescriber rate.

Those who choose to use GLP-1 drugs, originally intended for diabetes control, for weight management may have to pay out-of-pocket.

Patel stated that currently, there are active employers and entire states that are declining to cover weight loss indications.

If the U.S. Food and Drug Administration approves Ozempic for use in Type 2 diabetics with chronic kidney disease, as Patel predicts, it may compel insurance companies to broaden their coverage of the medication.

"The final package of data will be so compelling that it would be incorrect not to cover it, as it should surpass what we currently have available," she remarked. "I believe insurance companies will struggle with this."

Jared Holz, Mizuho Health Care Sector Strategist, anticipates challenges related to insurance coverage as more patients use GLP-1 drugs, potentially hindering widespread adoption.

"At some point, payers will say, 'We understand, but we cannot afford these at this volume without seeing the benefit, which may be in 10, 20, or 30 years,' and we don't know when the offset will occur," he said on CNBC's "Fast Money."

The health care sector is witnessing a growing divide between pharmaceutical companies such as Novo Nordisk and Eli Lilly, according to Holz.

"Perhaps in the history of the sector, there has never been such a significant disconnect in valuation between the peer group," he stated.

Supply constraints have made it difficult for patients to obtain dosages, which may affect the sustainability of growth trends for Novo Nordisk and Eli Lilly.

Holz stated that the companies are not generating enough revenue to satisfy investors, as the stocks are trading at a high price, according to his opinion.

Neither Novo Nordisk nor Eli Lilly provided a comment regarding the matter.